AxoSim Posters Featured at SOT 2024 Annual Meeting
News and BlogThe Society of Toxicology (SOT) brought together more than 5,000 people for its 63rd Annual Meeting and ToxExpo March 10 – 24 […]
Read MoreSelection of drug candidates is a difficult and imperfect process requiring predictive modeling. Too often, animal and other preclinical models are not predictive in humans. Without this knowledge, selection of the wrong candidate can result in losses of money, time, and resources. We aim to help navigate this path by providing rodent and human predictive in vitro modeling.
Our industry leading biomimetic platforms enable us to work with our clients and partners to apply predictive data assisting in identification of better drug candidates, earlier, and more accurately and efficiently.
1) Drug Discovery: Shortening the time to lead candidate selection with human targets in phenotypic assays.
2) Preclinical: Broadening the preclinical funnel while shortening the time to clinical candidate selection.
3) Clinical: Accelerating IND filing with improved translation a success.
AxoSim's NerveSim® platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
BrainSim® is a high quality 3D miniature brain organoid designed to serve as a human-relevant model in preclinical drug discovery.
The microBrain™ technology provides a physiologically-relevant human iPSC-derived screening platform for CNS drug discovery and toxicity testing.
The Society of Toxicology (SOT) brought together more than 5,000 people for its 63rd Annual Meeting and ToxExpo March 10 – 24 […]
Read MoreMore than 300 million people globally live with a rare disease, and just 100,000 live with Guillain–Barré Syndrome (GBS). Rare Disease Day […]
Read MoreAxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors —Serial Entrepreneurs Dale Pfost and David Weiner Bring Broad […]
Read MoreRESEARCH As Vyant Bio continues its wind-down, the neuroscience research assets of its subsidiary StemoniX have officially been picked up by AxoSim, a […]
Read MoreAt AxoSim, we frequently like to remind ourselves of our mission- empowering advancements in human neuroscience. We take a minute- away from the lab bench, protocols, schedules, budgets, and pipettes- and remember, that at the end of all the research, is people. Human beings that we know and love that are fighting daily battles with neurological diseases.